Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / OVA1




QA State: Curated
Short Name:
HGNC Name:

The OVA1 diagnostic test is comprised of five biomarkers: CA125, transthyretin (prealbumin), apolipprotein A1 (Apo A-1), beta-2 microglobulin, and transferrin. OVA1 is an In Vitro Diagnostic Multivariate Index Assay (IVDMIA) of Proteomic Biomarkers test that analyzes the serum levels of these five proteomic biomarkers. OVA1 is the first FDA approved test for assessing ovarian cancer risk in women previously diagnosed with an ovarian mass, and already scheduled for surgery. The OVA1 algorithm combines the results of these levels with information on the menopause status of the patient to classify the patient into a low- or high-risk group. The results of the OVA1 test can help determine patients needing referral to a gynecologic oncologist for their surgery.

Panel Details


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: Three
QA State: Curated


OVA1 is intended for women 18 years old and older who have a previously identified ovarian mass. It is not intended to be used as a widespread screening tool or for diagnostic purposes. The OVA1 test is used in conjunction with other clinical and radiographic data to determine referral to a gynecologic oncologist.


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.

2015 EDRN PI Orientation

The New and Continuing EDRN Principal Investigator Orientation will take place January 20–21, 2016 in Bethesda, Maryland.

Announcement 08/26/2015

Thank you to everyone who made the 29th EDRN Steering Committee Meeting a success. The orientation for new and continuing EDRN PIs will be held Wednesday-Thursday, January 20-21, 2016, on the NCI campus. More information will be available later this summer.

Announcement 06/30/2015

A funding opportunity for a new pancreatic cancer initiative, called The Pancreatic Cancer Detection Consortium (U01), has been released. For more information, please go to /grants/guide/ pa-files/ PAR-15-289.html.